Global Secondary Hyperparathyroidism Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Secondary Hyperparathyroidism treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Amgen Inc, EA Pharma Co Ltd, Lupin Ltd, Mitsubishi Tanabe Pharma Corp, Novadiol Inc and others.
A Significant contribution to the Secondary Hyperparathyroidism pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Secondary Hyperparathyroidism pipeline included 9 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Secondary Hyperparathyroidism condition and increased access to investments is encouraging growth of Secondary Hyperparathyroidism drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Secondary Hyperparathyroidism drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Secondary Hyperparathyroidism therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Secondary Hyperparathyroidism pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Secondary Hyperparathyroidism. Further, orphan drug status, fast track designation, grants awarded and other special status for Secondary Hyperparathyroidism pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Secondary Hyperparathyroidism pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Secondary Hyperparathyroidism Pipeline candidates-
A Significant contribution to the Secondary Hyperparathyroidism pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Secondary Hyperparathyroidism pipeline included 9 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Secondary Hyperparathyroidism condition and increased access to investments is encouraging growth of Secondary Hyperparathyroidism drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Secondary Hyperparathyroidism drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Secondary Hyperparathyroidism therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Secondary Hyperparathyroidism pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Secondary Hyperparathyroidism. Further, orphan drug status, fast track designation, grants awarded and other special status for Secondary Hyperparathyroidism pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Secondary Hyperparathyroidism pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Secondary Hyperparathyroidism Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Secondary Hyperparathyroidism drugs
- Late phase: Phase 3 and in-approval Secondary Hyperparathyroidism drugs
- Company overview
- Snapshot
- Secondary Hyperparathyroidism therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Secondary Hyperparathyroidism- Disease Overview
2.2 Secondary Hyperparathyroidism- Pipeline Snapshot
2.3 Secondary Hyperparathyroidism- Pipeline Drugs by Phase
2.4 Secondary Hyperparathyroidism- Pipeline Drugs by Company
2.5 Secondary Hyperparathyroidism- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Amgen Inc Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.2 EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.3 Lupin Ltd Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.4 Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.5 Novadiol Inc Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.6 OPKO Health Inc Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.7 TaiRx, Inc. Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.8 Takeda Pharmaceutical Co Ltd Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.9 Vidasym Inc Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Secondary Hyperparathyroidism- Phase 1 Drug Details
4.2 Secondary Hyperparathyroidism- Phase 1 Drug Overview
4.3 Secondary Hyperparathyroidism- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Secondary Hyperparathyroidism- Phase 2 Drug Details
5.2 Secondary Hyperparathyroidism- Phase 2 Drug Overview
5.3 Secondary Hyperparathyroidism- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Secondary Hyperparathyroidism- Phase 3 Drug Details
6.2 Secondary Hyperparathyroidism- Phase 3 Drug Overview
6.3 Secondary Hyperparathyroidism- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Secondary Hyperparathyroidism- Pre-clinical Phase Drug Details
7.2 Secondary Hyperparathyroidism- Pre-clinical Phase Drug Overview
7.3 Secondary Hyperparathyroidism- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Secondary Hyperparathyroidism- Disease Overview
2.2 Secondary Hyperparathyroidism- Pipeline Snapshot
2.3 Secondary Hyperparathyroidism- Pipeline Drugs by Phase
2.4 Secondary Hyperparathyroidism- Pipeline Drugs by Company
2.5 Secondary Hyperparathyroidism- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Amgen Inc Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.2 EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.3 Lupin Ltd Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.4 Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.5 Novadiol Inc Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.6 OPKO Health Inc Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.7 TaiRx, Inc. Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.8 Takeda Pharmaceutical Co Ltd Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
3.9 Vidasym Inc Secondary Hyperparathyroidism Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Secondary Hyperparathyroidism- Phase 1 Drug Details
4.2 Secondary Hyperparathyroidism- Phase 1 Drug Overview
4.3 Secondary Hyperparathyroidism- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Secondary Hyperparathyroidism- Phase 2 Drug Details
5.2 Secondary Hyperparathyroidism- Phase 2 Drug Overview
5.3 Secondary Hyperparathyroidism- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Secondary Hyperparathyroidism- Phase 3 Drug Details
6.2 Secondary Hyperparathyroidism- Phase 3 Drug Overview
6.3 Secondary Hyperparathyroidism- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Secondary Hyperparathyroidism- Pre-clinical Phase Drug Details
7.2 Secondary Hyperparathyroidism- Pre-clinical Phase Drug Overview
7.3 Secondary Hyperparathyroidism- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
